Page 18 - Monitoring Prostate Cancer to Guide Treatment Decision-Making
P. 18

STAMPEDE Trial Design




                                                              Patients eligible for STAMPEDE
                                     Men newly diagnosed as metastatic, node positive, or high-risk locally advanced,

                                                 or relapsing following RP and/or RT with high risk features


                                              Newly Diagnosed M1 Patients                    All Other Patients
                                       RANDOMISATION                                           RANDOMISATION


                                A      ADT                                               A     ADT (+ RT if N0 M0)


                                B      Arm A + zoledronic acid                           B     Arm A + zoledronic acid
     Closed for inclusion
     in late 2012               C      Arm A + docetaxel                                 C     Arm A + docetaxel

                                E      Arm A + ZA + docetaxel                            E     Arm A + ZA + docetaxel


                                G      Arm A + abiraterone                               G     Arm A + abiraterone

                                H      Arm A + RT to prostrate                        Docetaxel was given with prednisolone 10 mg daily.


          ADT = androgen deprivation therapy; RP = radical prostatectomy; RT = radiotherapy; ZA = zoledronic acid.
           James N, et al. Lancet. 2016;1163-77.
                                                                                                                                              18
   13   14   15   16   17   18   19   20   21   22   23